Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grade > 2 side effects were recorded. Additional data and marketing authorizations are awaited, but preliminary results in adolescents with extensive multidrug resistant virus are encouraging.
Thuret
Isabelle
I
Service d'Hématologie Pédiatrique, CHU Timone, Marseille, France.
Chaix
Marie-Laure
ML
Tamalet
Catherine
C
Reliquet
Véronique
V
Firtion
Ghislaine
G
Tricoire
Joëlle
J
Rabaud
Christian
C
Frange
Pierre
P
Aumaître
Hugues
H
Blanche
Stéphane
S
D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D009570:Nitriles; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines; D011760:Pyrrolidinones / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D013449:Sulfonamides; C451734:etravirine; D000068898:Raltegravir Potassium; D000069454:Darunavir